<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BUSULFAN</span><br/>(byoo-sul'fan)<br/><span class="topboxtradename">Busulfex, </span><span class="topboxtradename">Myleran<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg tablets; 6 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Potent cytotoxic alkylating agent that may be mutagenic and carcinogenic. Cell cycle nonspecific. Reduces total granulocyte
         mass but has little effect on lymphocytes and platelets except in large doses. May cause widespread epithelial cellular dysplasia
         severe enough to make it difficult to interpret exfoliative cytologic examinations from lung, breast, bladder, and uterine
         cervix.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Causes cell death by acting predominantly on slowly proliferating stem cells by inducing cross linkage in DNA, thus blocking
         replication. Acquired resistance may develop, probably due to intracellular inactivation of busulfan.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative treatment of chronic myelogenous (myeloid, granulocytic, myelocytic) leukemia for patients no longer responsive
         to radiation therapy or to previously tried antineoplastics. Does not appreciably extend survival time.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Polycythemia vera, severe thrombocytosis, as adjunct in treatment of myelofibrosis, allogenic bone transplantation in patients
         with acute nonlymphocytic leukemia.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Therapy-resistant chronic lymphocytic leukemia; lymphoblastic crisis of chronic myelogenous leukemia; bone marrow depression,
         immunizations (patient and household members), chickenpox (including recent exposure), herpetic infections. Safety during
         pregnancy (category D) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Men and women in childbearing years; history of gout or urate renal stones; prior irradiation or chemotherapy.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chronic Myelogenous Leukemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 48 mg/d until maximal clinical and hematologic improvement, may use 14 mg/d if remission is shorter than 3 mo<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.060.12 mg/kg/d or 1.84.6 mg/m<sup>2</sup>
<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at same time each day.</li>
<li>Give on an empty stomach to minimize nausea and vomiting.</li>
<li>Store in tightly capped, light-resistant container at 15°30° C (59°86° F), unless otherwise
            specified.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span> Major toxic effects are related to <span class="speceff-life">bone marrow failure; agranulocytosis</span> (rare), pancytopenia, thrombocytopenia, leukopenia, <span class="speceff-common">anemia</span>. <span class="typehead">Urogenital:</span> Flank pain, renal calculi, uric acid nephropathy, <span class="speceff-life">acute renal failure</span>, gynecomastia, testicular atrophy, azoospermia, impotence, sterility in males, ovarian suppression, menstrual changes, amenorrhea
      (potentially irreversible), menopausal symptoms. <span class="typehead">Respiratory:</span> Irreversible <span class="speceff-life">pulmonary fibrosis</span> ("busulfan lung"). <span class="typehead">Skin:</span>  Alopecia, hyperpigmentation. <span class="typehead">Other:</span> Endocardial fibrosis, dizziness, cholestatic jaundice, infections. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Busulfan may decrease <span class="alt">urinary 17-OHCS</span> excretion, and may increase <span class="alt">blood and urine uric acid</span> levels. Drug-induced cellular dysplasia may interfere with interpretation of <span class="alt">cytologic studies.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid,</b>
<b>sulfinpyrazone</b> may increase <b>uric acid</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 4 h. <span class="typehead">Duration:</span> 4 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 1050% excreted in urine within 48 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Normal leukocyte count is usually achieved in about 2 mo.</li>
<li>Monitor the following: Vital signs, weight, I&amp;O ratio and pattern. Urge patient to increase fluid intake to 1012 [8
            oz] glasses daily (if allowed) to assure adequate urinary output.
         </li>
<li>Monitor for and report symptoms suggestive of superinfection (see Appendix F), particularly when patient develops leukopenia.</li>
<li>Lab test: Baseline Hgb, Hct, WBC with differential, platelet count, liver function, kidney function, serum uric acid; repeat
            at least weekly.
         </li>
<li>Avoid invasive procedures during periods of platelet count depression.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician any of the following: Easy bruising or bleeding, cloudy or pink urine, dark or black stools; sore mouth
            or throat, unusual fatigue, blurred vision, flank or joint pain, swelling of lower legs and feet; yellowing white of eye,
            dark urine, light-colored stools, abdominal discomfort, or itching (hepatotoxicity).
         </li>
<li>Use contraceptive measures during busulfan therapy and for at least 3 mo after drug is withdrawn.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>